New contract, page-24

First 24 Last

TDA

11,411 Posts.

137

07/10/14

00:18

Post #: 14083251

Originally posted by IndiJo ↑

TDA may have a different list but what I have been following

Column 1 Column 2 Column 3

1 Development Name Type Indication

2 SAR339658 Anti-VLA 2 mAb Multiple Sclerosis

3 SAR228810 Anti-protofibrillar AB mAb Alzheimer’s disease

4 SAR252067 Anti-LIGHT mAb Crohn’s disease

5 Alirocumab PCSK9 mAb Cholesterol

6 SAR113244 Anti-CXCRS mAb Systemic lupus erythematosu

7 Dupilumab IL4RαmAbAtopic Dermatitis;
Asthma;
Nasal polyposis

Dupilumab has 3 target indications so you could almost count that as three. Though best leave it at one until you see some dosages for later stage trials being over 300mg which is not a bad rule of thumb cut off point for viscosity/volume/concentration exceeding PFS and AIDs capability

First cab off the rank is hopefully Alirocumab and Sanofi-REGN chasing Amgen and monthly dosing (Awaits reporting on Choice 1 program) Then its Dupilumab by my ruler

Guess with this in the bag UNS may let the cat out of the bag re Sanofi using Finesse for some of the drugs with as Sarilumab, Alirocumab etc. As you point out kar18na the announcement points a finger towards REGN

Good work to those loyal folk who hung around.

Expand

lol knew you would be all over it Indi, not hard when they were recruiting for it was it

We can see the indications here:

https://www.linkedin.com/jobs2/view/12926093

and even as early as here for these:

http://advoke27.rssing.com/chan-14254138/all_p1448.html

More to come guys, it's just getting warm imo!

UNS Price at posting: 41.5¢ Sentiment: Buy Disclosure: Held

2 Upvote

0 Great analysis

Top Stories

TNC

True North increases silver metal at QLD's Vero deposit by 20%

Revolutionary inverter technology leads the clean energy charge

Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling

NEU

Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress

From the Floor with Federal Opposition Leader Peter Dutton at Diggers & Dealers 2024

HZR

Hazer Group reports ten days of continuous operation at graphite-manufacturing test facility

Dale Gillham's weekly wrap: picking resilient stocks in a volatile global market

TKM

Trek Metals jumps 5% as gold & REE drill run kicks off at Christmas Creek in the Kimberley

Emerald & Azure score Digger & Dealer awards

Bitcoin: Current State of Play & Where to Next | Swyftx

There are more pages in this discussion • 86 more messages in this thread...

First 24 Last

Add UNS (ASX) to my watchlist

	Column 1	Column 2	Column 3
1	Development Name	Type	Indication
2	SAR339658	Anti-VLA 2 mAb	Multiple Sclerosis
3	SAR228810	Anti-protofibrillar AB mAb	Alzheimer’s disease
4	SAR252067	Anti-LIGHT mAb	Crohn’s disease
5	Alirocumab	PCSK9 mAb	Cholesterol
6	SAR113244	Anti-CXCRS mAb	Systemic lupus erythematosu
7	Dupilumab	IL4RαmAbAtopic	Dermatitis; Asthma; Nasal polyposis

New contract, page-24

Top Stories

True North increases silver metal at QLD's Vero deposit by 20%

Revolutionary inverter technology leads the clean energy charge

Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling

Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress

From the Floor with Federal Opposition Leader Peter Dutton at Diggers & Dealers 2024

Hazer Group reports ten days of continuous operation at graphite-manufacturing test facility

Dale Gillham's weekly wrap: picking resilient stocks in a volatile global market

Trek Metals jumps 5% as gold & REE drill run kicks off at Christmas Creek in the Kimberley

Emerald & Azure score Digger & Dealer awards

Bitcoin: Current State of Play & Where to Next | Swyftx

Featured News